Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Key selective action features: No Growth Hormone Receptor Binding: Does not activate GH receptors responsible for IGF-1 stimulation and systemic growth effects Preserved Glucose Metabolism: No impact on blood sugar regulation, insulin sensitivity, or diabetic risk markers No Tissue Growth Effects: Does not promote muscle hypertrophy, organ growth, or cell proliferation pathways Adipose-Specific Targeting: Works primarily through beta-3 adrenergic receptors concentrated in fat tissue No IGF-1 Elevation: Clinical trials confirmed no changes in serum IGF-1 levels at therapeutic doses Isolated Lipolytic Action: Maintains the fat-breaking properties of growth hormone fragment 176-191 without broader effects Selective Mechanism: Structural differences from full-length GH prevent binding to receptors mediating non-fat-related effects Clinical Validation: Human studies in 900+ participants confirmed selective fat metabolism without systemic hormonal changes The following guide provides detailed analysis of AOD-9604 s selective action and why this selectivity matters for safe, targeted fat metabolism
Integrating BPC-157 with Rehabilitation BPC-157 enhances healing but works best as part of a comprehensive approach that includes appropriate rehabilitation
Formula: Peptide components
Pen Dosage Chart Dosage & Protocols Variations Standard Research Protocol Dose: 0.3 1.2 mg (= 1248 clicks) Duration: 8 12 weeks Frequency: Once weekly Cycle Interval: 4 weeks off before repeating Goal / Description: Baseline protocol for appetite regulation and body weight modulation in experimental models
The scientific evidence surrounding peptides and weight loss is highly variable and depends entirely on which specific peptide compound is being considered
US$ 28.37
US$ 21.62
US$ 23.64
